Posted by Michael Wonder on 26 Jul 2018
PTAC recommends immune checkpoint inhibitors for certain patients with advanced urothelial carcinoma
25 July 2018 - The publication of the minutes of the May 2018 PTAC meeting reveals new outcomes.
PTAC reviewed applications from Merck Sharp & Dohme for pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) who are not eligible for cisplatin-containing therapy (first-line treatment) and for patients after failure of a platinum-containing chemotherapy regimen (second-line treatment) and a funding application from Roche for atezolizumab for the treatment of patients with locally advanced or metastatic UC following progression on platinum-containing chemotherapy (second-line treatment).
The Committee recommended pembrolizumab and atezolizumab be funded with low priority for the second-line treatment of patients with locally advanced or metastatic UC.
